Bolognese M A; Teglbjærg C S; Zanchetta J R; Lippuner K; McClung M R; Brandi M L; Høiseth A; Lakatos, Péter; Moffett A H; Lorenc R S; Wang A; Libanati C
(2013)
Denosumab is an approved therapy for postmenopausal women with osteoporosis at high or increased risk for fracture. In the FREEDOM study, denosumab reduced fracture risk and increased bone mineral density (BMD). We report ...